Articles tagged with Glucose Production
Researchers developed fluorescent molecular probes to detect glucose levels in living animals, enabling real-time visualization of sugar uptake. The technology also enables the detection of elevated glucose in living systems, including zebrafish with diabetes-like mutations.
Researchers found that short and irregular weekday sleep significantly disrupts glucose metabolism, increasing type 2 diabetes risk. Even with extended weekend sleep, the body's ability to process glucose is impaired. Regular sleep patterns are crucial for glucose regulation and may impact the development of insulin resistance.
A KAUST researcher has created a highly sensitive glucose detector based on a thin-film transistor that can measure glucose levels in saliva with high accuracy. The device uses an enzyme to oxidize glucose present in the saliva, producing electrons that indicate the glucose concentration.
Researchers at Tulane University have discovered that following a low-carbohydrate diet can lead to reduced hemoglobin A1c levels and improved fasting glucose levels among individuals with unmedicated diabetes and prediabetes. The study suggests that a low-carb diet may be a useful approach for preventing and treating Type 2 diabetes.
Researchers have identified a novel enzyme that catalyzes the formation of glycosidic bonds in complex sugar moieties. The discovery provides fresh insights into carbohydrate metabolism and offers a breakthrough for the synthesis of sugar chains, which play key roles in various biological processes.
New research from RCSI shows that an irregular body clock can drive inflammation in the body's immune cells, leading to chronic diseases like heart disease and diabetes. Macrophages without a body clock take up more glucose and produce inflammatory products.
New research reveals how lung cancer progression disrupts circadian glucose regulation, fueling cancer cell growth. The study identifies REV-ERB? as a key regulator and suggests targeting this protein to suppress cancer cell growth.
Researchers at KAIST successfully produced carminic acid from glucose in engineered Escherichia coli, overcoming the need for complex purification processes and protein contaminants. The development of a generally applicable C-glucosyltransferase also enables the production of other valuable natural products.
A novel engineered C. glutamicum strain can produce high-level glutaric acid from glucose, breaking the record for the highest titer ever reported. The new strategy employs systems metabolic engineering strategies, including introducing Pseudomonas putida genes and optimizing culture conditions.
Researchers have developed a new strain of microorganisms that can efficiently produce fatty acids and biodiesels from glucose. The resulting strains produced the highest concentrations ever reported by microbial fermentations, making them a potential game-changer for sustainable energy production.
A Texas A&M-led study reveals that transcription factor Foxo1 plays a crucial role in regulating blood glucose levels and may serve as a key therapeutic target for preventing Type 2 diabetes. By understanding the molecular mechanism of Foxo1, researchers aim to develop novel interventions for controlling blood glucose homeostasis.
Colorado State University chemists have synthesized a biorenewable, biodegradable polymer called bacterial poly(3-hydroxybutyrate) or P3HB. The new chemical synthesis route produces P3HB with similar performance to bacterial P3HB but at a faster and more cost-effective scale.
A new study reveals that having a meal increases oxygen consumption in human brown adipose tissue (BAT) as much as cold exposure does. This finding suggests that eating may be an effective way to activate BAT and support metabolic health.
Researchers at UC San Diego School of Medicine have mapped out beta cell growth pathways that could be exploited to regenerate cells. This new information opens the door for finding drugs that stimulate these pathways to improve blood sugar levels in people with diabetes.
Researchers from TSRI and Harvard Medical School identified a new class of compounds that reduce glucose production in the liver, improving insulin sensitivity and glucose balance. The compound SR-18292 modifies PGC-1α protein, leading to reduced glucose production and offering potential for anti-diabetes treatment.
Researchers at WashU Medicine developed a new strategy to slow glucose production in the liver, which can lead to more effective drugs for type 2 diabetes. The approach involves inhibiting a protein involved in making glucose, demonstrating potential for treating millions of people affected by the condition.
A Yale-led research team has discovered the molecular mechanism behind insulin's role in regulating liver glucose production and how it fails in patients with type 2 diabetes. The findings reveal that inflammation in fatty tissue leads to increased hepatic glucose production, highlighting a potential target for new treatments.
A UT Southwestern Medical Center study identified phosphatidic acids as a new potential therapeutic target for controlling high blood sugar in type 2 diabetes. Inhibiting or reducing production of phosphatidic acids may help regulate glucose levels.
Researchers at Salk Institute discover molecular switch controlling liver glucose production, potentially offering new avenue for treating insulin-resistant type II diabetes. The discovery may lead to agents that can selectively damp down activity of the IP3 spigot and calcineurin accelerator to lower blood sugar levels.
Researchers develop a new technique to dynamically regulate metabolic pathways in microbes, boosting the production of biodiesel by threefold. The dynamic sensor-regulator system (DSRS) can detect metabolic changes and control gene expression to optimize productivity.
Researchers discovered SRC-1, a steroid receptor coactivator, plays a crucial role in regulating the liver's glucose production. The study found that mice lacking SRC-1 have impaired glucose production, leading to hypoglycemia.
Researchers discovered that high glucose levels in diabetic tissue lead to reduced vascular endothelial growth factor production and impaired HIF-1a function. Deferoxamine, an iron-binding drug, has been shown to improve wound healing by restoring HIF-1a-p300 interaction, leading to increased growth factor production.
Researchers at Salk Institute discover how obesity triggers diabetes by activating ER stress, leading to abnormal glucose production in the liver. CRTC2 plays a key role in this process, with ATF6a competing for its binding site.
Researchers at the Salk Institute have discovered a two-stage fasting-response mechanism that ensures glucose production in the brain is tightly regulated. CRTC2 and FOXO1 proteins play key roles in this process, with SIRT1 serving as a nutrient sensor that switches between them.
Researchers found a connection between an immune protein and glucose levels, offering a new avenue for treating diabetics who don't respond to traditional insulin-based treatments. The protein, defensin HNP-1, inhibits glucose-producing genes and reduces blood sugar levels in both normal mice and diabetic rats.
Researchers at the Salk Institute have identified a new target for diabetes treatment: the protein TORC2. TORC2 regulates glucose production in liver cells and its activation can improve insulin sensitivity. The discovery holds promise for developing more effective diabetes medications.
New research reveals that accumulated liver lipids originate from serum fatty acids, newly produced fatty acids within the liver, and dietary fatty acids. The study also highlights the potential role of endocannabinoids in regulating liver metabolism and appetite control. Additionally, a companion paper explores the relationship betwee...